Regenerative therapies for equine degenerative joint disease: a preliminary study.
Degenerative joint disease (DJD) is a major cause of reduced athletic function and retirement in equine performers. For this reason, regenerative therapies for DJD have gained increasing interest. Platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) were isolated from a 6-year-old donor horse. MSCs were either used in their native state or after chondrogenic induction. In an initial study, 20 horses with naturally occurring DJD in the fetlock joint were divided in 4 groups and injected with the following: 1) PRP; 2) MSCs; 3) MSCs and PRP; or 4) chondrogenic induced MSCs and PRP. The horses were then evaluated by means of a clinical scoring system after 6 weeks (T1), 12 weeks (T2), 6 months (T3) and 12 months (T4) post injection. In a second study, 30 horses with the same medical background were randomly assigned to one of the two combination therapies and evaluated at T1. The protein expression profile of native MSCs was found to be negative for major histocompatibility (MHC) II and p63, low in MHC I and positive for Ki67, collagen type II (Col II) and Vimentin. Chondrogenic induction resulted in increased mRNA expression of aggrecan, Col II and cartilage oligomeric matrix protein (COMP) as well as in increased protein expression of p63 and glycosaminoglycan, but in decreased protein expression of Ki67. The combined use of PRP and MSCs significantly improved the functionality and sustainability of damaged joints from 6 weeks until 12 months after treatment, compared to PRP treatment alone. The highest short-term clinical evolution scores were obtained with chondrogenic induced MSCs and PRP. This study reports successful in vitro chondrogenic induction of equine MSCs. In vivo application of (induced) MSCs together with PRP in horses suffering from DJD in the fetlock joint resulted in a significant clinical improvement until 12 months after treatment.
Global Stem cell Technology, Meldert-Lummen, Belgium.
Sarah
S
Broeckx
Equine Veterinary Practice Dr Suls, Weert, The Netherlands.
Marieke
M
Zimmerman
Department for Biomechanics, ETH Zurich, Zurich, Switzerland.
Sara
S
Crocetti
Equine Veterinary Practice Dr Suls, Weert, The Netherlands.
Marc
M
Suls
Equitom Equine Hospital, Meldert-Lummen, Belgium.
Tom
T
Mariën
Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland.
Stephen J
SJ
Ferguson
Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Koen
K
Chiers
Department of Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Luc
L
Duchateau
Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland ; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Alfredo
A
Franco-Obregón
Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland.
Karin
K
Wuertz
Global Stem cell Technology, Meldert-Lummen, Belgium.
Jan H
JH
Spaas
D053674:Aggrecans / Q000378:metabolism; D000818:Animals; D002454:Cell Differentiation; D020219:Chondrogenesis / Q000502:physiology*; D024043:Collagen Type II / Q000378:metabolism; D006736:Horses; D007592:Joint Diseases / Q000378:metabolism / Q000628:therapy / Q000662:veterinary*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods / Q000662:veterinary*; D053657:Platelet-Rich Plasma / Q000378:metabolism*; D016896:Treatment Outcome
D053674:Aggrecans; D024043:Collagen Type II